Attia Mohamed F, Akasov Roman, Alexis Frank, Whitehead Daniel C
Department of Chemistry, Clemson University, Clemson, South Carolina 29634, United States.
National University of Science and Technology MISIS, Leninskiy Prospect 4, 119991 Moscow, Russia.
ACS Biomater Sci Eng. 2020 Dec 14;6(12):6671-6679. doi: 10.1021/acsbiomaterials.0c01082. Epub 2020 Nov 5.
We developed four types of -phenylene-bridged periodic mesoporous organosilica NPs (-P PMO NPs) with tailored physical parameters including size, morphology, porosity, and surface area using a new polymer-scaffolding approach. The particles have been formulated to facilitate the codelivery of small-molecule hydrophobic/hydrophilic cargos such as model anticancer drugs (i.e., doxorubicin hydrochloride (DOX) and -benzylguanine) and model fluorescent dyes (i.e., rhodamine 6G and Nile red). -P PMO NPs were synthesized via a cetyltrimethylammonium bromide (CTAB)-directed sol-gel process using two different organic solvents and in the presence of polymeric scaffolding constituents that led to morphologically distinct PMO NPs despite using the same organosilane precursors. After the formulation process, the polymeric scaffolding agent was conveniently washed away from the PMO NPs. Extensive analyses were used to characterize the physicochemical attributes of the PMO NPs such as their chemical composition, morphologies, etc. Spherical and rod-shaped PMOs of diameters ranging between 79 and 342 nm, surface areas between 770 and 1060 m/g, and pore volumes between 0.79 and 1.37 cm/g were prepared using the polymer-scaffolding approach. The performance of these materials toward drug-loading capacity, cytotoxicity, and cancer cell internalization was evaluated. Interestingly, the designed particles exhibited significantly high payloads of drugs and dyes (up to 78 and 94%, respectively). Cellular studies also demonstrated exceptional biocompatibility and marked internalization into both human breast cancer MCF-7 and glioblastoma U-87 MG cells. Further, DOX also possessed a noticeable release from particles and accumulation in cell nuclei with increased incubation time in vitro. Ultimately, this work validates the controlled design and synthesis of PMO NPs using a polymer-scaffolding approach and highlights the potential of these materials as excellent delivery systems for combination therapy with high loading capability to improve the therapeutic index for cancers.
我们采用一种新的聚合物支架方法,开发了四种具有定制物理参数(包括尺寸、形态、孔隙率和表面积)的亚苯基桥连周期性介孔有机硅纳米粒子(-P PMO NPs)。这些颗粒被设计用于促进小分子疏水/亲水货物的共递送,如模型抗癌药物(即盐酸多柔比星(DOX)和 -苄基鸟嘌呤)和模型荧光染料(即罗丹明6G和尼罗红)。-P PMO NPs是通过十六烷基三甲基溴化铵(CTAB)导向的溶胶 - 凝胶过程,使用两种不同的有机溶剂,并在聚合物支架成分存在的情况下合成的,尽管使用相同的有机硅烷前体,但导致了形态上不同的PMO NPs。在制备过程之后,聚合物支架剂很方便地从PMO NPs中洗去。广泛的分析用于表征PMO NPs的物理化学属性,如它们的化学成分、形态等。使用聚合物支架方法制备了直径在79至342 nm之间、表面积在770至1060 m²/g之间、孔体积在0.79至1.37 cm³/g之间的球形和棒状PMO。评估了这些材料在药物负载能力、细胞毒性和癌细胞内化方面的性能。有趣的是,设计的颗粒表现出显著高的药物和染料负载量(分别高达78%和94%)。细胞研究还证明了其出色的生物相容性以及在人乳腺癌MCF - 7和胶质母细胞瘤U - 87 MG细胞中的显著内化。此外,DOX在体外随着孵育时间的增加也从颗粒中显著释放并在细胞核中积累。最终,这项工作验证了使用聚合物支架方法对PMO NPs进行可控设计和合成,并突出了这些材料作为具有高负载能力的联合治疗优秀递送系统的潜力,以提高癌症的治疗指数。